The management of complex cardiovascular disease has changed markedly with the development of new strategies of care, an increasing amount of scientific evidence-based data and appropriate use criteria. Applying this plethora of information and synthesizing it for presentation and recommendations to the patient and family have assumed central importance. To facilitate this process of patient centric evidence-based care multidisciplinary Heart Teams have become identified as cornerstones. While specific strategies for implementation of these teams will vary, this broad approach will become the standard of cardiovascular care. (J Am Coll Cardiol 2013;61:903-7)
The concept of a Heart Team has become the subject of increasing interest in treating cardiovascular disease. While a team-based approach has been part of the practice in other medical fields such as oncology and is also a mainstay in organ transplant programs, it has more recently been emphasized in treating cardiovascular disease. This emphasis has been the result of the widespread attention given to the concept in the SYNTAX (SYNergy Between PCI [percutaneous coronary intervention] With TAXUS and Cardiac Surgery) trial (1) (2) (3) (4) (5) and now with the introduction of transcatheter aortic valve replacement (TAVR) (6 -12) .
The rationale for team-based care is to optimize the management of complex patient care issues, which has become increasingly difficult because of the development of new devices and approaches, the burgeoning amount of scientific information on novel strategies both from randomized clinical trials (RCTs) and large registries, and the focus on patient groups at higher risk for adverse outcomes because of advanced age or comorbidities. Although evidence-based criteria for diagnostic and/or therapeutic procedures have been emphasized, this approach remains difficult even with use of appropriate criteria (13) (14) (15) (16) (17) (18) (19) (20) . While recommendations based on these approaches make intuitive sense, they remain somewhat imprecise because of the lack of specificity in accurate risk prediction for an individual patient (21) (22) (23) (24) (25) , as well as differing patient expectations about those risks. The metrics on which patients base their expectations vary widely; for example, the expectations of a 92-year-old patient may be different from those of a 65-year-old patient in terms of a hierarchical endpoint composed of various components such as death, myocardial infarction, stroke (either major or minor), need for repeated procedures, or quality of life. Such variation is a central component of the Institute of Medicine priorities that care should be customized to the patient's needs and values and that the patient should be the source of control.
The central goal of patient-centric care requires that the patient and family be sufficiently educated about the alternatives available so that their expectations can be met as fully as possible (26 -28) . Given the wide range of information available from different cardiovascular specialties and the potential for individual physician biases, team-based care has great potential merit. This has now been codified in guideline documents, and the Heart Team has emerged as a class 1 indication in both the 2010 European Society of Cardiology and the European Association for CardioThoracic Surgery Guidelines for Coronary Revascularization (29) and the 2012 ACC/AHA Guidelines for Coronary Artery Bypass Grafting surgery (16) . The goal of the multidisciplinary Heart Team is to offer a balanced and complementary approach to patient care by joint and shared decision making among different medical care stakeholders such as cardiac surgery and interventional cardiology. By exploring the multiple options available and sharing them with patients and their families where applicable, more optimal shared decision making is achieved, along with a tailored recommendation for therapy for a more informed and engaged patient. From a professional team point of view, subsequent joint participation in procedures can not only improve the skill sets of all involved medical and surgical personnel but also elevate the cognitive interchange that occurs among the specialties.
The importance of the Heart Team concept is typified in two recent examples from the field of coronary revascularization therapy and the newly approved procedure of TAVR.
Coronary revascularization.
A plethora of data has accumulated about the relative roles of percutaneous versus surgical revascularization in the management of patients with complex coronary artery disease (1,14,16,20 -23,29, 30 -32) . It must be remembered in this regard that either revascularization approach should be layered against the fundamental backdrop of "optimal medical therapy."
In some clinical circumstances, the situation is straightforward, for example, an acute coronary syndrome with an isolated single discrete distal right coronary artery stenosis in which PCI can be considered the treatment of choice with little or no disagreement) or a patient with significant angina, multiple coronary occlusions, and other severe complex disease (with a high SYNTAX score: Ͼ33) (1) with adequate target vessels and viable myocardium in whom surgical revascularization is the treatment of choice.
Many patients, however, fit between these two polar opposites, and in this continuum, multiple considerations exist. There is a burgeoning amount of information from RCTs (e.g., the SYNTAX [1] [24] ), and, most recently, the largest and most robust data set from the National Heart, Lung, and Blood Institute ASCERT [ACCF-STS Database Collaboration on the Comparative Effectiveness of Revascularization Strategies] trials (30, 31, 35) , performed jointly by investigators from the Society of Thoracic Surgeons and the American College of Cardiology. Outcome data from both RCTs and registries are invaluable in constructing as complete a picture as possible, although each has advantages and disadvantages (Table 1 ). This is complicated by the fact that there is often some degree of discordance between the very carefully controlled RCTs and the larger, more "real-world" registries. In addition, the two revascularization strategies are markedly different, each with its own risk-benefit ratios. Synthesizing the information from the different data sets and strategies is difficult. It is uncommon for any single trial to provide the definitive answer for all patients in all settings, so each data set must be evaluated as part of the whole picture. The specific "truth" identified in each trial may be the result of many factors, for example, patient population, method of ascertainment of a specific endpoint (e.g., stroke), duration of follow up, and adjunctive treatment; and other characteristics as well as methodology of trial performance, quality of data, robustness of the conclusions, and relevance to the specific patient at hand must all be considered. In addition, unmeasured confounding variables may potentially dramatically alter conclusions. Although it is a common, perhaps universal, goal of patients to take the "least invasive" 7 approach, that approach may not necessarily be the optimal strategy, especially for the long-term outcome. Implementation of a Heart Team can help to put these issues into perspective for patients and their families. This multidisciplinary team, including an experienced cardiac surgeon, interventional cardiologist, and primary cardiologist, working together can help to focus on specific patient considerations and expectations. This team can then evaluate the specific clinical setting in the context of evolving data from both RCTs and registries, as well as their individual experience to fully inform the patient and family about the risks/benefits ratio of any specific revascularization recommendation. Combining first-hand patient expectations, their consideration of hierarchical endpoints such as death, myocardial infarction, stroke, and need for subsequent procedures with available scientific data forms the basis for personalized treatment recommendations. Transcatheter aortic valve replacement. A second illustrative example of the central importance of the Heart Team is in the treatment of severe aortic stenosis, which has been transformed by the development of transcatheter approaches to aortic valve replacement compared to the standard of care of surgical aortic valve replacement. More than 50,000 TAVR procedures have been performed worldwide (6 -12,36). The scientific evidence available for these two approaches comes in the form of multiple single-center, multicenter, and national registries, as well as from one RCT.
Available data indicate that: 1) many patients with severe aortic stenosis are not offered traditional surgical aortic valve replacement, either because of high or even prohibitive surgical risk or patient preference; 2) in patients at prohibitive surgical risk, compared with standard medical therapy, TAVR results in improved survival; 3) in patients at high risk for surgical treatment but who are operable, TAVR results in similar survival rates at 2 years of follow-up; and 4) there are differences in risk profiles between surgical aortic valve replacement and TAVR.
In the randomized PARTNER A (Placement of AoRTic traNscathetER Valve) trial, although there was no significant difference in mortality between the two groups, patients undergoing TAVR had an increase in periprocedural strokes, both major and minor, at 30 days and at 1 year and increased major vascular complications (37) . On the other hand, surgical AVR was associated with more major bleeding and more atrial fibrillation. The conclusions were that both approaches were acceptable in high-risk patients but that there were different periprocedural hazards.
These essential but complex pieces of information must be communicated to referring physicians and to patients and their families in terms of patient selection and risk/benefit ratio as well as procedural performance. This process has been the focus of multiple expert consensus documents in this field. These documents deal not only with patient selection and procedural performance but also center and operator credentialing and experience. A central component of each of these documents has been the Heart Team.
In the case of TAVR, the Heart Team consists of the cardiovascular surgeon, the interventional cardiologist, a structural heart disease expert, and imaging specialists, among others. This Heart Team approach has been recommended by multiple specialty societies and is also mandated by regulatory and reimbursement agencies including the U.S. Food and Drug Administration and Centers for Medicare and Medicaid Services based upon several issues (6 -8,38) . These issues include the facts that there is already an established surgical option, which has been tested over the past 25 years; patients are elderly with multiple comorbidities, making any approach more complicated with higher risks; consideration of TAVR includes evaluation of peripheral arterial access and underlying coronary artery disease, as well as the severity of the aortic stenosis and the presence or absence of LV dysfunction; and, finally, procedural performance improves when both cardiac surgeons and interventional cardiologists perform the procedure together. This combination of facts including the risk/benefit ratio of either surgical AVR, TAVR, or medical therapy requires assessment by a multidisciplinary team to be comfortable with the recommendation to optimize patient care and to educate the patient and the family.
As can be seen from the aforementioned examples, the Heart Team has become an integral part of the practice of modern cardiovascular care to optimize patient selection through identification of the risk/benefit ratio of different strategies, evaluation of the increasingly large and robust data sets of both RCTs and observational registries, patient and family education, and procedural performance and follow-up. Composition and implementation. The composition of the Heart Team will vary depending on the specific clinical situation and will also vary from institution to institution. In the case of coronary revascularization, it should consist of the cardiovascular surgeon, the interventional cardiologist and the primary cardiologist, who is most familiar with the nuances of the specific patient and family considerations. In the case of TAVR, the team also will include consideration of involvement of expert imaging specialists, neurologists, vascular medicine physicians, and cardiac anesthesiologists, all of whom are important in patient selection and procedural performance.
Implementation of a Heart Team approach is not without multiple potential issues and problems. From a logistical standpoint, with current health care systems, work flow to gather the Heart Team participants could become disrupted and less efficient. In this regard, unavailability of particular team members at any specific time may further disrupt the process.
Establishing formats for interaction by the Heart Team will be essential. In some institutions, there will the development of a structural heart disease center to facilitate the process (36) . Such a dedicated center will include availability 905 JACC Vol. 61, No. 9, 2013
Holmes, Jr, et al. March 5, 2013:903-7 The Heart Team of Cardiovascular Care of members of the relevant Heart Team and facilities for patient interaction and image assessment. There will also be both print and video educational material for the patient and family. This center will focus on patient evaluation, selection, and education, with intensive efforts at discussion of the risk/benefit ratio and alternative strategies of care. In the case of coronary revascularization, a variety of approaches has been undertaken. In some institutions, patient cases with complex multivessel disease are presented at a combined medical and surgical conference held weekly or more often and the respective merits of specific approaches discussed, which can then be transmitted to the patient by the primary cardiologist. In other institutions, the system used in the SYNTAX trial may be implemented, wherein the interventional cardiologist and cardiovascular surgeon visit with the patient and the family together after the diagnostic angiogram is obtained to discuss relative advantages and disadvantages of each potential procedure that could be performed so that the patient can be fully informed.
There may be some instances in which the optimal approach is straightforward and the Heart Team is not needed. However, despite these challenges, approaches to implementation must be developed. In the field of coronary revascularization, for example, the application of PCI at the time of diagnostic angiography in patients with complex or multiple vessel disease will become more restricted. Instead, patients will undergo diagnostic angiography in this setting, and the procedure will be electively stopped to allow full discussion with members of the Heart Team and the patient and the family. This separation of diagnostic angiogram from potential PCI will need to be discussed with the patient and the family ahead of time and the importance of it emphasized. Failure to implement a Heart Team is increasingly not an option as the Heart Team is mandated in certain clinical situations by societal guidelines, and procedural reimbursement has been linked to it. Health Care systems will need to evolve to include these health care teams in optimizing patient-centered care.
Conclusions
Evolving strategies of care under some cardiovascular conditions have identified the central role of the Heart Team in optimizing patient selection, procedural performance, and follow-up care and in enhancing the process of patient education and informed consent. The composition of this team may vary depending on the clinical setting and among institutions. The Heart Team approach is timely and has become mandatory in light of evolving options in therapeutics, in the resurgence of focus on patient-centered care, and for optimizing delivery of care and its reimbursement strategies. The heart team concept forms the heart of modern cardiovascular care. 
